Health-related quality of life (HRQoL) measurement in cystic fibrosis (CF) allows the inclusion of the patient's perspective in research and clinical practice. HRQoL scales have been used for many purposes and this review focuses on how HRQoL measurement has been implemented in CF research and care. Specifically, the review considers 1) the instruments used to measure HRQoL, 2) the factors that influence how people report HRQoL, 3) the monitoring of HRQoL in clinical practice, 4) HRQoL as an outcome measure in interventions and clinical trials and 5) whether HRQoL can predict survival. The challenge for the future is to use the available information to develop and evaluate psychological interventions that would be expected to improve HRQoL in children and adults with CF. Chronic Respiratory Disease 2009; 6: 31-41
Introduction
Health-related quality of life (HRQoL) measurement in cystic fibrosis (CF) allows the inclusion of the patient's perspective in research and clinical practice. Typically, HRQoL is defined as a multidimensional construct comprised of several domains as reported by the patient (e.g., physical, social and psychological functioning, respiratory symptoms, treatment burden, and body image). Asking the patient "how they are" or about the effectiveness of treatments is nothing new. HRQoL instruments, however, can provide a standardized, valid, and reliable way of gaining the patient's perspective as to "how they are" and the benefits and limitations of interventions. The correlations between clinical variables and HRQoL are often poor; therefore, HRQoL can provide "added value" because it can supply information not captured by other outcomes. In a recent trial, only HRQoL provided additional information to lung function from several secondary endpoints. 1 HRQoL scales have been used for many purposes. This review focuses on how HRQoL measurement has been implemented in CF research and care. Specifically, the review will consider 1) the instruments used to measure HRQoL, 2) the factors that influence how people report HRQoL, 3) the monitoring of HRQoL in clinical practice, 4) HRQoL as an outcome measure in interventions and clinical trials, and 5) whether HRQoL can predict survival. A search of the literature was undertaken. OVID (Medline, Embase, British Nursing Index), EBSCOhost (CINAHL, PsycINFO, PsycARTICLES), Web of Knowledge, PubMed, Science Direct, Cochrane Library, and clinicaltrials.gov were searched to locate all full papers in the English language that included "cystic fibrosis" and "quality of life" in the title, abstract, or keywords. Extra searches on "well-being" were carried out in databases where this key word was accepted. scale) have produced inconsistent findings in CF. 2 Different types of scales have been used and these have been discussed in previous reviews. [3] [4] [5] [6] They include ad hoc, 7, 8 global rating of change, 9 generic, [10] [11] [12] [13] [14] utility, 15, 16 non-standardized profiles, 17 respiratory-specific (Chronic Respiratory Disease Questionnaire [CRDQ], 18 St George's Respiratory Questionnaire [SGRQ] 19 ), and CF-specific scales (Cystic Fibrosis Questionnaire [CFQ], [20] [21] [22] Cystic Fibrosis Quality of Life Questionnaire [CFQoL], 23 Questions on Life Satisfaction Scale [FLZ-CF], 24 DISABKIDS 25 ). Only the CFQ has scales for both children and adults. Apart from the CF-specific scales, the scales that have some CF psychometric data for investigators to consult are the Short Form 36 (SF-36), 26 and the respiratory-specific CRDQ 27 and SGRQ. 28 The psychometric data from these scales are less robust than those for the CF-specific measures.
More recently, two CF-specific patient-reported outcome measures, which may be described as HRQoL scales, have been developed. The Memorial Symptom Assessment Scale (MSAS) has been amended and evaluated for use in adults with CF. The MSAS CF is a measure of physical and psychological symptom burden with psychological, respiratory, and gastrointestinal domains. 29 The Living with CF Questionnaire (LCFQ) focuses primarily on the psychosocial aspects of HRQoL for youth with CF (e.g., relationship strains, parent/friend support, illness worries, and self-care/adherence). 30 Both scales require further evaluation but have provided interesting preliminary data concerning gender differences.
There has been little consensus on how to measure HRQoL in CF at a conceptual or operational level, and there is no "gold standard." Furthermore, CF disease has "evolved" and since the first CF HRQoL scales were developed, there have been noticeable changes in the disease and available therapies. Different HRQoL instruments provide different information, even for similarly named domains (for example, social functioning can refer to a variety of concepts). Alternatively, domains may have different names, yet measure similar concepts. Even the CF-specific HRQoL scales measure different things. As domain names can be vague, there is a need to look at the instruments on an item basis to assess what is being measured. For clinical trials, regulatory authorities have imposed much needed guidance 31 and it is likely that future CF research will incorporate a more diverse range of patientreported outcome measures. 32 
Factors influencing HRQoL in CF
Understanding the determinants of HRQoL may assist in the development of interventions to improve it. How a person with CF reports their HRQoL may be influenced by many demographic, clinical, psychological, and social variables. Some of these factors are likely to be inter-related but it is useful to have them in mind when designing, analysing, and interpreting HRQoL studies as they may influence the findings.
Demographic variables

CF and healthy populations
Research from around the world suggests that people with CF, despite the burdens that the disease and its treatments impose on them, are psychologically well-adjusted and generally report a good HRQoL on many domains of generic and CF-specific measures. 2, [33] [34] [35] [36] [37] When comparing people with CF with healthy populations, global QoL results showed that generally adults with CF had a similar or better global QoL than healthy controls (e.g., satisfaction with broader life domains such as independence, work, relationships, and family). 2, 37 However, those with the poorest lung function (FEV 1 < 30% predicted) reported the poorest global QoL. 37 Using instruments with physical and psychological domains, children and adults with CF typically report lower scores than healthy populations for most physical domains but a similar HRQoL for psychosocial domains, 2, 38, 39 and it is noteworthy that adolescents with CF were less likely than the general population to have a recognized psychiatric disorder. 36 It may seem contrary to expectation that people with severe life-limiting disease can report a good HRQoL. This may be due to a phenomenon known as "response shift"; a reevaluation of the meaning of life and subsequently adapting to changing conditions. 40
Age and gender
After adjustment for other predictors and using CFspecific scales, increasing age has been associated with poorer physical and social functioning, career opportunities, and relationships, but a better HRQoL regarding concerns for the future. 41, 42 Chronic Respiratory Disease
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Again, this may be explained by a re-evaluation of what is important in life. Gender differences in HRQoL exist in CF. Women (girls 7-13 years, adolescents, and adults) have reported a poorer life quality than similaraged men on several HRQoL domains of generic and disease-specific scales. 22, 43, 44 On a global level, after controlling for age and FEV 1 , female gender was associated with lower global health, mental health, and general health perception scores in adolescents. 43 However, women had high levels of satisfaction concerning housing and partnership, although over the age of 35 were at risk of low life satisfaction. 42 Using CF-specific scales, women reported a poorer HRQoL for physical functioning, chest symptoms, and emotional functioning, 41, 45, 46 although they reported a better HRQoL concerning body image and weight. 41, 45 It is notable that girls reported poorer chest symptoms than boys although there was no difference in their FEV 1 , suggesting that gender differences are already evident in childhood. 22 Living with CF appears to have a greater emotional impact on adolescent girls compared with boys. Girls reported more illnessrelated strains and worries, including emotional strains, lower self-esteem and poorer adherence to some therapies (eating high-fat foods, taking medication, more likely to suppress coughing). 30 Indeed, women have reported a higher overall respiratory and psychological symptom burden. 29 Given the consistent findings that women report poorer HRQoL, it is intriguing that they have a more accurate perception of their objective clinical status than men. 44 Further work is required to focus on the causes of these gender differences and on potential interventions to improve HRQoL for all those living with CF.
Employment and culture
Increased life expectancy has resulted in more people with CF entering the workforce. In all, 68% of adults believed that their CF was a barrier to employment, although very few had sought vocational guidance. 47 The factors associated with work status were evaluated in 183 adults. Half the participants were working, and age and lung function were similar for those working and nonworking, although those in employment reported less depression and a higher educational level. 48 In a separate study, workers reported a better HRQoL across most domains of the CFQ. Non-working people were more likely to have poorer lung function, an intravenous access device, more severe infection, and nutritional interventions. 49 The more hours worked per week has also been associated with having a sense of control over the disease, lower hospital admission rates, and older age. 47 However, full-time work has been negatively associated with HRQoL and this may be due to the combined challenges that full-time work and timeconsuming treatments pose. 50 In general, it is likely that the work environment provides a form of social support and may also serve as a distraction from CF. Indeed, social support is important as better HRQoL was reported by those living with a partner or living with their parents, even for adults with CF. 50 Employment issues are important as the cultural expectation in Western society is that individuals work. There is a societal value placed on occupations; it partially defines who you are and allows financial independence.
Cross-cultural differences in adolescents with CF and their healthy peers have been reported. Both English CF and control groups reported a poorer HRQoL than their respective German counterparts across several domains of the SF-36. 51 People with CF living in rural Australia have been shown to have poorer health compared with those living in metropolitan zones. Although the authors report no statistically significant differences on the CFQ domains between adolescents in a CF Centre or those managed by a CF rural outreach service, outreach teens reported consistently higher scores, with some scores approximately 20 points higher. It is likely that the small sample size precluded the detection of significant P values. 46 Understanding cultural differences is important if studies collect data from different countries or cultures. Direct cultural comparisons of HRQoL have been made in other conditions. [52] [53] [54] [55] In a cancer study, cultural differences were observed across 13 countries for all aspects of HRQoL at baseline, but more importantly, the magnitude of the change over time was not consistent among nations. 55 Clinical variables FEV 1 % predicted is an important indicator of disease status and those with better lung function tend to report a better HRQoL. 21, 37, 44 However, studies have reported weak to moderate correlations between HRQoL and lung function in children and adults, 2,23,34,41,44,56,57 and FEV 1 % predicted was positively associated with all domains of the CFQoL in multivariate analyses. Even so, it accounts for only a small proportion of variability in HRQoL scores. 37, 44, 56, 57 Being newly colonized with Pseudomonas aeruginosa 50 and respiratory exacerbations have been shown to have a negative impact on HRQoL that is not explained by demographic factors, lung function, or nutritional status. 38 Recent pulmonary exacerbations predicted poorer HRQoL across many physical and psychosocial domains. 38, 50 Conversely, improvement in lung function following treatment for respiratory infections has been shown to be accompanied by an improvement in HRQoL. 23, 57 Additionally, using a sinus-specific quality of life measure (SNOT-16), the severity of sinus disease has been shown to negatively impact on the quality of life of children with CF. 58 CF disease progression produces an increase in other clinical manifestations and interventions. Urinary incontinence in women has been associated with a poorer HRQoL across several CFQoL domains. 59 Enteral tube feeding, diabetes, having an intravenous access device or being on the transplant waiting list were also found to be independently, negatively associated with many HRQoL domains. Although important associations were identified, again much of the variance remained unexplained. 41 A few studies, predominantly with small samples and different methods of measurement, suggest that half to two-thirds of children and adults with CF report pain on a regular basis, 29, [60] [61] [62] [63] [64] [65] which is associated with a poorer quality of life. [64] [65] [66] [67] In two studies with larger samples of adults, approximately one-quarter to one-third of patients reported moderately strong to severe pain. 64, 65 There are many aspects of CF that may cause pain with headache, backache, abdominal, chest, and limb pain most frequently reported. These data suggest that pain is worthy of further investigation and draw attention to the importance of routinely assessing pain in people with CF.
Psychosocial variables
A further avenue of investigation has been to examine the role of psychosocial variables in explaining HRQoL. Understanding the determinants of HRQoL, particularly the role of coping and mood, may suggest possible interventions to improve the HRQoL of people with CF.
Coping
The CF literature consists of several descriptive studies of the ways in which people cope, [68] [69] [70] [71] [72] [73] but only a few have attempted to evaluate the extent to which coping explains patient-reported HRQoL. 52, [74] [75] [76] When compared with a healthy control group on the Hearth Hope Index, adults with CF reported lower levels of hope especially for the item "scared about the future," but in contrast they reported greater inner strength. 76 Using the Hunter Opinions and Personal Experiences Scale, the majority of adolescents were hopeful and positive about their future. Lack of hope for the future was correlated with poorer HRQoL in most domains of the CFQ. 36 Two German studies administered generic HRQoL and coping questionnaires to adolescents and adults with CF. After controlling for Shwachman score, body mass index and lung function coping accounted for an additional 12% of the variance in overall HRQoL. Social comparison (e.g., "I told myself that others were worse off") was related to better HRQoL, whereas depressive coping (e.g., "I asked myself again and again, why me?") was associated with poorer HRQoL. 56 The second study reported that 56% of the overall HRQoL variance was explained by coping and the time burden of treatments. Poor HRQoL was associated with a "rumination" coping style (meditating on negative aspects) and the time required for daily therapy, whereas a good HRQoL was associated with seeking social support, good lung function, and body mass index. 75 More recently, CF-specific HRQoL and coping scales have been used to evaluate how much of the variance was explained by coping for each CFQoL domain, once the known important demographic and clinical variables were controlled for. Optimistic (a focused, determined, and optimistic belief about the future) and distraction coping (doing things to forget CF) emerged as significant predictors of how adults with CF report their HRQoL. Optimism was consistently associated with a superior quality of life, whereas distraction was consistently associated with a poorer quality of life. This was particularly true for emotional and social functioning and interpersonal relationships. 74 It has also been documented that self-efficacy (optimistic self-beliefs that one can cope with life demands) is an additional factor in explaining HRQoL. Controlling for demographic and lung function variables, those with high levels of self-efficacy reported a better respiratory-specific (SGRQ) and global QoL. 77
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Anxiety and depression
Optimistic coping is the predominant way of coping for people with CF. 68, 69, 74 However, a recent study using the Beck Depression Inventory and the CFQ has reported that 30% of adults with CF screened positive for depressive symptoms. Depressive symptoms were associated with a poorer HRQoL across all CFQ domains even after controlling for lung function. 78 Similarly, those reporting depressive or anxious symptoms on the Hospital Depression and Anxiety Scale also reported a poorer HRQoL across many CFQ domains. Interestingly, a comparison of normal and borderline/clinical scores showed that different aspects of HRQoL were associated with anxiety and depression. Those with high anxiety scores reported poorer respiratory symptoms, health perceptions, vitality, treatment burden, social and emotional functioning, whereas those with high depression scores reported eating disturbances, poorer body image, and emotional functioning. In this work, the prevalence of anxiety and depression in adults with CF was similar to their healthy peers with 30% screening positive for anxiety and 13% for depression. 79 Screening for and treating depression may improve HRQoL; hence, further robust studies using multivariate modeling are required to assess the impact of mood on HRQoL and clinical status.
Monitoring HRQoL in clinical practice
Repeated HRQoL assessments should be able to provide useful information concerning the individual's adaptation to the disease and be used to improve the care delivered to patients. However, HRQoL measurement in CF remains largely a research endeavor. HRQoL measures are increasingly being used to evaluate the effectiveness of interventions, but there are few data as to how HRQoL scores naturally vary over time. Their use in routine clinical management has been shown to be feasible, 50 but lack of time and expertise in scoring and interpreting the data may prohibit HRQoL monitoring in clinical settings. Health professionals already ask a lot of patients, so if HRQoL monitoring is to be undertaken there should be a clear rationale for doing so and the information should be used to benefit patient care. At six-monthly intervals, over a 2-year period, 38 children with CF and their parents were administered the Child Health Questionnaire (CHQ) and the children completed an ad hoc CF-specific mea-sure adapted from a diabetes instrument. Neither parental nor child reports changed much over time. The only domain on the child and parent CHQ to decrease over time was general health perceptions. As no clinical data are reported, it is difficult to know whether HRQoL changes might be expected. 40, 80 However, domain scores on the Nottingham Health Profile changed little over 2 years in 152 adults, even in those whose lung function had decreased. 81 Over an 18-month period, between 2 and 16 repeated FLZ assessments were collected on 108 adolescents and adults. The most salient finding was the stability of HRQoL over time, but longitudinal case analyses showed an oscillation of scores around a personal average. Repeat HRQoL scores consisted of peaks and troughs, but without a general trend of increasing or decreasing and HRQoL was independent from the course of FEV 1 . 50 Current HRQoL measures are based on the assumption that people use measurement scales consistently. 40, 82 However, a person may respond differently over time not only because their health or HRQoL has changed but also because they have altered their perceptions of what health or HRQoL means to them. This has important implications for the longitudinal assessment of HRQoL, particularly the effects of interventions as a change in HRQoL may reflect an intervention effect, a response shift or a combination of both. To illustrate this, the SEIQoL was used in a trial (an individualized QoL measure in which individuals decide the domains most salient to them). Unadjusted SEI-QoL scores showed no impact of treatment at 3 months. However, when asked to rate their baseline QoL retrospectively, patients rated it lower than they had done initially. If this new baseline score was used, a significant treatment effect was observed; hence, an improvement in QoL was only seen when response shift was taken into account. 83 
Interventions and clinical trials
The CF literature contains a variety of interventions in which HRQoL has been evaluated as an endpoint (transplant, segregation, newborn screening, inpatient rehabilitation, and home versus hospital IVs). Most striking is the absence of psychosocial interventions. In a Cochrane review, there was insufficient evidence to conclude that psychological therapies are effective in the management and care of CF disease, 84 and the use of HRQoL measurement in these studies was rare.
Transplant
The improvement in HRQoL is the most compelling argument for lung transplantation, 85, 86 yet it is rarely measured routinely. Those in need of transplantation report restrictions on most aspects of their HRQoL. [87] [88] [89] Burker, et al. compared CF patients awaiting transplant with other types of end-stage lung disease. Those with CF tended to be younger and were twice as likely to be working. They reported fewer difficulties in performing hygiene, household, and feeding tasks on the Sickness Impact Profile. They were also less anxious and reported greater levels of social support. However, 15 of 58 people with CF died while waiting for transplant compared with 4 of 52 patients with other lung diseases, suggesting that the patients with CF may actually be sicker. 87 Similarly, two recent studies using the SF-36 and respiratory-specific scales compared people with CF and those with other end-stage lung conditions who were awaiting transplant. People with CF reported better physical and psychological functioning, less breathlessness, and lower levels of anxiety. 88, 89 However, no differences occurred on the Beck Depression Inventory, General Health Questionnaire, or Perceived Stress Scale. 89 CF lung transplant recipients also have good outcomes. 90 When evaluating the association of clinical variables and HRQoL, those who were post-transplant tended to report a much higher quality of life for physical functioning, social functioning, treatment issues, and chest symptoms on the CFQoL. This is not surprising given that transplantation is the most radical intervention in terms of clinical improvement. 41 In a study comparing the HRQoL of lung transplant recipients with healthy individuals, the Quality of Life Profile for Chronic Disease was administered. The scores for the transplant recipients were similar to those of a healthy population, although those with CF, single lung transplant recipients, and those who were older reported poorer physical ability. 91 Comparison of HRQoL scores between CF and non-CF lung transplant patients indicated that both groups reported significant improvements in HRQoL up to 31 months following transplantation. 92, 93 People with CF were more likely to be younger, working, or going to school before transplant and reported greater energy, mobility, and better sleep. 92 The Munich Life Dimensions List was administered to 66 lung transplant patients, the majority of whom had CF. Dramatic improvements on many aspects of physical, psychological, social, and relationship domains were reported, but recipients also reported that some aspects of HRQoL became more important and that their perceptions and values had changed. 94 These studies are cross-sectional and no data comparing HRQoL pre and post-transplant are available.
Segregation
Chronic bacterial infection is a major contributory factor to progressive lung damage. Some CF centers have identified epidemic colonization of Burkholderia cepacia complex or certain strains of P. aeruginosa, and there is evidence that these bacteria are more pathogenic and transmissible. [95] [96] [97] [98] Successful infection control is being achieved through strict segregation practice, 95 although it has been acknowledged that segregation and isolation may have a negative impact on emotional well-being. 99 It may be expected that having B. cepacia complex would have a negative effect on HRQoL as it brings further uncertainty about the future. However, there was no evidence of any association between B. cepacia complex and any of the CFQoL domains in either univariate or multivariate analysis in patients colonized for at least 1 year. 41 This may appear counter intuitive given the segregation policies in operation in CF centers, but the data suggest that even if there had been negative psychological effects at diagnosis, patients had adapted to the knowledge and the consequences of living with B. cepacia complex. In a recent questionnaire study, 51% of adults reported that their HRQoL would not suffer if they avoid others with CF; however, 23% reported that their HRQoL would be significantly affected. 100 
Newborn screening
A study from the Wisconsin Neonatal Screening Programme investigated whether newborn screening had a subsequent effect on the HRQoL of the child. The CHQ was administered to 36 children (15 screened, 21 control) aged [10] [11] [12] [13] [14] [15] . No impact of the screening intervention on HRQoL was observed, although there was an interesting trend for the changes in health domain to be poorer in the nonscreened group. Parental HRQoL was not evaluated
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Inpatient rehabilitation
A CF inpatient rehabilitation programme has been shown to improve HRQoL outcome. In a 4-week programme designed to improve the physical, emotional, and social functioning of people with CF, the FLZ was administered at baseline and 1 month after the intervention. Rehabilitation consisted of strict daily exercise training and physiotherapy, psychosocial support two or three times per week, nutritional counseling twice a week, and patient education regarding physiotherapy and medical therapy. Following the programme, participants were more satisfied with general, health-related, and CF-specific aspects of their lives. The strongest effects were observed for breathing, physical condition, leisure activities, satisfaction with general health, and integration of therapy into daily routine. 102 Whether HRQoL improvements are maintained long-term requires investigation.
Home versus hospital IV's
Home intravenous (IV) therapy is popular and has the advantages of cost-saving by freeing hospital beds, avoiding cross-infection, and the patient and family are able to continue their normal lives. However, a crucial question is whether home and hospital treatments provide equivalent outcomes. A few studies with small samples tend to suggest that the issue of home versus hospital treatment is complex, with different types of HRQoL improvements occurring dependent on the treatment setting. In the only parallel designed randomized controlled trial (RCT) of home compared with hospital IVs, HRQoL was the primary outcome (CRDQ). The authors reported no differences concerning dyspnoea and emotional functioning, but the fatigue, mastery, and total scores were poorer for home patients. However, improved HRQoL was reported in the areas of personal, family, sleeping, eating, and total disruption for home, compared with hospital admissions. There were no differences in clinical outcome. 103 Subsequently, a study of adults with CF compared home and hospital treatment with patients receiving IV antibiotics for acute respiratory exacerbations. Lung function improved more in the hospi-tal group although HRQoL was better when undertaking IVs at home. The authors did not compare the pre-post change values of each group, but it appears that CFQoL change scores improved for career and relationships in the home group. 104 Conversely, being hospitalized for an exacerbation was associated with improvements in psychosocial HRQoL (measured by CHQ and SF-36), whereas receiving treatment at home was associated with deterioration. 105 The site of treatment may be the preference of physician, patient, and/or family and this may influence HRQoL reporting. Indeed, the complexity of home and hospital interventions warrants further investigation.
Clinical trials
Regulatory authorities and the good clinical practice guidelines now require the inclusion of patientreported outcomes in clinical trials as an additional outcome parameter. 31 Recently, the EuroCareCF HRQoL Outcome in Clinical Trials Working Group has produced guidelines for the measurement of HRQoL in clinical trials. In 2005, Abbott and Hart 106 published a review of RCTs in CF where HRQoL was measured. Sixteen trials were identified but the reporting of HRQoL information was poor and not one trial evaluated in the review provided conclusive results concerning HRQoL. A variety of reasons contributed to this including a lack of rationale for the choice of instrument and the domains being measured, the lack of a full description of the scale nor an explanation of the scoring method or appropriate reporting of patient and patient proxy data, and incomplete summary information about HRQoL baseline values, making it difficult to interpret the importance of the reported changes.
Since 2005, many trials are being undertaken that include HRQoL as a primary or secondary endpoint (clinicaltrials.gov). Of those published and located, it is evident that the measurement, interpretation, and reporting of HRQoL data has improved. [107] [108] [109] Briefly, two trials have clearly shown that inhaled hypertonic saline is an effective therapy in CF with improvements in some CFQ domains, 107, 108 and a further trial has reported that growth hormone treatment improves clinical status and appropriate aspects of HRQoL (weight, body image) in children with CF. 109 However, in some instances, HRQoL measurement remains problematic [110] [111] [112] [113] Some studies are still failing to report the measure being used, the timing of assessments, present domain scores rather than total scores, or present change scores especially when baseline HRQoL scores differ.
Tremendous effort goes into designing robust, critic-proof clinical trials. This review outlines many factors that contribute to HRQoL reporting, which have important implications when using HRQoL as an outcome measure. Stratification based on clinical factors is common, but for psychological factors it is rare; however, patient perceptions are important. After all, placebo controls are required in clinical trials because of patient beliefs and expectancy effects. The use of HRQoL instruments in clinical trials necessitates further investigation and debate, especially if HRQoL is to be evaluated as the primary endpoint.
HRQoL and survival in CF
The question of whether aspects of HRQoL can predict mortality in people with CF is an important one, as potentially, this could lead to behavioural and/or cognitive interventions to prolong life. The first study to investigate HRQoL and survival comes from the United Kingdom. 114 Demographic, clinical, and HRQoL variables (CFQoL and SF-36) were recorded for 223 adults with CF. These data were used as baseline scores to evaluate the prognostic association of HRQoL and subsequent survival, over a 10-year period. The physical functioning domain of the CFQoL and the pain domain of the SF-36 were important predictors of survival, even in the same multivariable model. When adults with CF rate their physical functioning, they appear to be aware of something important that is not identified by traditional risk factors. When HRQoL domains were considered one at a time, in addition to physical functioning and pain, the chest symptoms and emotional responses domains of the CFQoL and the change in health domain of the SF-36 also appeared to be predictors of survival. 114 The potential importance of the changes in health domain suggests that longitudinal models which take account of changes over time may be better at predicting survival.
The mechanisms underlying the association between patient-reported aspects of HRQoL and length of survival in CF are not clear but deserve closer investigation. These results add to the growing realization of the importance of patient-reported outcomes in the management of CF, and provide credibility for their use in clinical trials.
Future directions
The insights that patients have concerning their health and how they report these are important. A good deal is known regarding the determinants of HRQoL in CF and these variables should be considered when designing studies and interpreting results. As CF is a changing disease, there are now important topics that are not assessed in the CF-specific scales 115 and this may limit their future usefulness. There is no room for complacency in HRQoL measurement: researchers require a grasp of what HRQoL scales are actually measuring to anticipate when changes would be expected.
The cross-sectional nature of most studies does not allow the assessment of cause and effect, and this remains to be elucidated in longitudinal work. Studies are required to evaluate the natural progression of HRQoL reporting over many years. The future input of HRQoL data into registries may enable robust evaluations of HRQoL over time and allow further evaluation of patient-reported outcomes in predicting survival. The challenge for the future is to use the available information to develop and evaluate psychological interventions that would be expected to improve HRQoL in children and adults with CF.
